Substance Misuse Services, Nottinghamshire Healthcare Trust, Nottingham, UK.
Schizophr Bull. 2013 Jan;39(1):226-9. doi: 10.1093/schbul/sbr140. Epub 2012 Jan 30.
To carry out an up-to-date comprehensive survey of the content and quality of intervention trials relevant to the treatment of people with schizophrenia.
Data were extracted and analyzed from 10,000 trials on the Cochrane Schizophrenia Group's Register.
Source, type and date of publication, country of origin, language, size of trial, interventions, and outcome measures.
In the last decade, there has been a great increase in the number of trials relevant to schizophrenia and an improvement in the accessibility to reports. The number of trials per year is rising (currently ∼600/year) with China now producing 25% of the annual total. The number of reports of trials is increasing at an even greater rate due to multiple publications. Drug trials still dominate (83%) although an increasing proportion of studies are now evaluating psychological therapies (21%). Trials remain small (median 60 people) and often employ new nonvalidated outcomes scales (2194 different scales were employed with every fifth trial introducing a new rating instrument).
A more collaborative, pragmatic, and patient-centered approach is necessary to produce larger schizophrenia trials. Wider consultation and careful consideration of all relevant perspectives would result in trials with greater clinical utility and direct value to people with the illness and their families or carers.
对与精神分裂症治疗相关的干预试验的内容和质量进行最新的全面调查。
从 Cochrane 精神分裂症组注册处的 10000 项试验中提取和分析数据。
来源、类型和出版日期、原产国、语言、试验规模、干预措施和结局指标。
在过去十年中，与精神分裂症相关的试验数量大幅增加，报告的可获得性也有所改善。每年的试验数量呈上升趋势（目前约为 600/年），中国目前占每年总数的 25%。由于多次发表，试验报告的数量增长更快。药物试验仍然占主导地位（83%），尽管现在越来越多的研究正在评估心理疗法（21%）。试验仍然规模较小（中位数为 60 人），并且经常使用新的非有效结局量表（共使用了 2194 种不同的量表，每 5 个试验中就有 1 个引入了新的评分工具）。
需要采取更协作、务实和以患者为中心的方法来开展更大规模的精神分裂症试验。更广泛的咨询和对所有相关观点的仔细考虑，将产生更具临床实用性和直接价值的试验，为患有该疾病的患者及其家属或照顾者提供帮助。
